VIVIMIND(TM), Canada's scientifically proven natural health product to protect memory function, is available starting today



    A new generation of memory protection

    To access a multimedia version of this release, please visit
    http://www.ovos.com/vivimind/index.htm

    LAVAL, QC, Sept. 2 /CNW Telbec/ - OVOS Natural Health Inc., a wholly
owned subsidiary of BELLUS Health Inc. (NASDAQ:   BLUS; TSX: BLU), announces
that VIVIMIND(TM), the company's first natural health product, is available
starting today on the Internet and progressively at over 2,000 retail points
of sale, including major drug, grocery and mass merchandise stores and natural
health stores across Canada. It is expected to be available at more than
3,000 points of sale by year-end. Targeted to aging baby boomers, VIVIMIND(TM)
protects memory function and is expected to address a largely underserved
self-care market by providing a scientific, evidence-based health solution. A
branded natural health product manufactured to the highest practice standards,
VIVIMIND(TM) is backed by 15 years of significant scientific research,
including clinical testing with over 2,000 individuals in 50 U.S. and
17 Canadian medical centres.(1)
    "This is good news for otherwise healthy aging baby boomers who notice
that they have started to forget small, everyday things, such as the names of
people they have just been introduced to or where they have put their car
keys. These are common signs of memory impairment," said Dr. Serge Gauthier,
Neurologist, McGill Centre for Studies in Aging, Montreal. "Clinical studies
have shown that VIVIMIND(TM) can help protect a region of the brain associated
with memory decline during the course of aging."
    Believed to be the result of biological and chemical changes, mild memory
decline occurs in many adults as part of the normal aging process.(2) For
example, memory decline is a common trait of Age Associated Memory Impairment
(AAMI) which is highly prevalent across diverse groups of individuals,(3)
affecting close to one in three people aged 60 to 78 years old.(2)
    "I get many questions about a natural alternative for the protection of
memory loss in my practice; most people get very concerned when their memory
starts letting them down," said Dr. Ruth Anne Baron, a naturopathic doctor
practicing in Toronto. "We should all take measures to keep our brains healthy
and VIVIMIND(TM) may play an important role to protect memory function as we
get older."
    "As people get older they become more concerned about memory glitches or
those tip-of-the-tongue frustrations when a name or word is forgotten and I am
often asked about alternative, natural ways to protect against memory loss,"
said Mr. Jean-Yves Dionne, pharmacist and consultant specializing in natural
health products. "Science has shown that VIVIMIND(TM) could play an important
role in protecting memory function and can be an important natural addition to
a healthy lifestyle in helping people take measures to maintain memory
function as they age."

    The science behind VIVIMIND(TM)

    Developed internationally with investments already amounting to several
hundreds of millions of dollars, VIVIMIND(TM) is a patented, natural health
product based on the naturally occurring ingredient homotaurine, a natural
amino acid with unique properties, found in certain seaweed. VIVIMIND(TM)
(homotaurine) is proven to have beneficial effects on preserving memory,
learning and other cognitive performances:(4)

    
    - In a clinical study conducted in Canada and the U.S. using brain scans
      (magnetic resonance imaging), VIVIMIND(TM) provided a statistically
      significant improvement with 68% less loss of brain volume in the
      hippocampus (a brain region responsible for learning and memorization)
      versus the untreated individuals;
    - Individuals taking VIVIMIND(TM) improved cognitive performance by 33%
      versus the untreated group. Notably, VIVIMIND(TM) helped to protect
      against loss of memory, comprehension ability and planning and
      execution skills.

    "Our flagship brand, VIVIMIND(TM), is in a class by itself," commented Mr.
Gary Schmid, President and Chief Executive Officer, OVOS Natural Health Inc.
"We are very proud to stand behind the science and research involved in
bringing this natural health product to Canadians. With VIVIMIND(TM), we are
pioneering a new business and scientific model in the natural health product
industry."
    VIVIMIND(TM) is recommended to be taken daily. The recommended adult dose
is one to two tablets twice a day, in the morning and the evening (preferably
at mealtime). The 50 mg tablets are available in 30- or 60-tab blister packs.

    For more information and to order, please visit www.vivimind.com.

    About OVOS Natural Health

    OVOS Natural Health Inc. is BELLUS Health's new, wholly owned
nutraceutical subsidiary devoted to the commercialization of brands made with
quality ingredients under Good Manufacturing Practice standards that can be
trusted to deliver self-care, evidence-based health solutions. For more
information, please visit www.ovos.com.

    About BELLUS Health

    BELLUS Health is a global health company focused on the development and
commercialization of products to provide innovative health solutions to
address critical unmet needs. For more information, please visit
www.bellushealth.com.

    About BELLUS Health Group

    The BELLUS Health Group is comprised of a group of companies located in
Canada, the United States and Europe, presently with approximately
105 employees focused on the development and commercialization of
nutraceutical, pharmaceutical and consumers goods products to provide
innovative health solutions to address critical unmet needs.

    Forward-Looking Statement

    Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond BELLUS Health
Inc.'s (formerly known as Neurochem Inc.) control. Such risks include but are
not limited to: the impact of general economic conditions, general conditions
in the pharmaceutical, nutraceutical and/or consumers goods industries,
changes in the regulatory environment in the jurisdictions in which the BELLUS
Health Group does business, stock market volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation, that actual
results may vary once the final and quality-controlled verification of data
and analyses has been completed, as well as other risks disclosed in public
filings of BELLUS Health Inc. Consequently, actual future results may differ
materially from the anticipated results expressed in the forward-looking
statements. The reader should not place undue reliance, if any, on any
forward-looking statements included in this news release. These statements
speak only as of the date made and BELLUS Health Inc. is under no obligation
and disavows any intention to update or revise such statements as a result of
any event, circumstances or otherwise, unless required by applicable
legislation or regulation. Please see the Annual Information Form of BELLUS
Health Inc. for further risk factors that might affect the BELLUS Health Group
and its business.

    (TM) Trademark of OVOS Natural Health Inc.

    References:

    1. North American and European Phase III clinical trials - data on file
       BELLUS Health Inc.
    2. Koivisto, K, et al. Prevalence of Age-Associated Memory Impairment in
       a randomly selected population from eastern Finland. Neurology
       1995;45:741-747 Available at:
       www.neurology.org/cgi/content/abstract/45/4/741
    3. Krasuski, Jack S. Behavior and Aging: 2000. Department of Psychiatry,
       University of Illinois at Chicago; 2000 (accessed July 30, 2008)
       Available at:
      
http://www.psych.uic.edu/education/courses/behav_science2000/krasuski/behavi~1
/sld009.htm).
    4. Post-hoc analysis of a 78-week Phase III North American study.
       Publication in preparation.
    

    B-ROLL FOOTAGE AND MEDICAL EXPERTS ARE AVAILABLE




For further information:

For further information: Lise Hébert, Ph.D., Vice President, Corporate
Communications, BELLUS Health Inc., (450) 680-4572; Roch Landriault, Sylvie
Robitaille, NATIONAL - Montreal, (514) 843-2345, (514) 843-2354; Margaret
Antkowski, NATIONAL - Toronto, (416) 848-1392; Richard Gilhooley, NATIONAL -
Vancouver, (604) 638-7451


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890